1Ishikawa T,Utoh M, Sauada N,et al. Tumor selective delivery of 5-fluorouracil by capecitabine,a new oral fluoropyrimidine carbamale,in human cancer xenografts [ J ]. Biochem Pharmoco1,2003,55 ( 7 ) : 1091-1097.
2Rossi D, Alessandroni P, Catalano V ,et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer [ J ]. Clin Breast Cancer, 2007,7( 11 ) :857-860.
3Seidman AD, O'Shaughnessy J, Misset JL. Single-agent capecit-abine: a reference treatment for taxane-pretreated metastatic breast cancer [ J ]. Oncologist, 2002,7 ( Suppl 6) : 20-28.
4Maroun J A. Capecitabine in the management of colorectal cancer[ J ]. Exp Rev Anticancer Ther,2001,32( 1 ) :327-333.
5Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma[J]. JNatl CancerInst, 1996, 88(16):1110- 1117.
6Tsukamoto Y, Kato Y, Ura M, et al. Investigation of 5-FU disposition after oral administration of capecitabine, a tripleprodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue betwcen human and xenograft model[J]. Biopharm Drug Dispos, 2001, 22(1): 1-14.
7Ishikawa T, Utoh M, Sawada N, et al. Tumor selective dehvery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [J].Biochem Pharmacol, 1998, 55(7): 1091-1097.
8Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts[J]. Cancer Res, 1998, 58(3) :685-690.
9Ishikawa T, Fukase Y, Yamamoto T, et al. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine) [J]. Biol Pharm Bull, 1998, 21(7) :713- 717.
10Schuller J, Gassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J]. Cancer Chemother Pharmacol, 2000, 45(4) :291-297.
